Design Synthesis and Biological Evaluation of Heterocyclic Molecules as Potential Anticancer Agents
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Cancer cells exhibit a heightened reliance on aggressive glycolysis to produce ATP and support their rapid proliferation. When glycolysis is disrupted, it can impede tumor growth, making glycolytic inhibitors a promising target for anticancer treatment. Monocarboxylate transporters 1 and 4 play crucial roles in facilitating the movement of glycolytic byproducts like lactate and pyruvate in and out of cancer cells. Inhibiting these transporters represents an innovative strategy to halt tumor growth. In this research, A library of 151 molecules were synthesized belonging to different scaffolds such as coumarins, flavonoids, quinazolinones, indole cyanoacrylate and cyanoacrylic acid derivatives linked with N-benzyl linker, indazole cyanoacrylic acid derivatives, indazole Schiff base, indazole-3-carboxamide, indole-3-cyanoacrylate, indazole based compounds linked with N-phenylpropanamide,, and 3-phenylindazole based compounds linked with N-phenylacetamide. The synthesized molecules were purified and characterized by using Mass, IR, 1H NMR, and HPLC.
newlineAll the synthesised molecules were evaluated for 5 human cancer cell lines i.e, cervical (SiHa), breast (MDA-MB-231), breast (MCF-7), lung (A-549) and normal moused embryonic fibroblast (NIH/3T3) cells via MTT assay. Results obtained from the biological evaluation suggested that compounds 214, 225, 249, and 263 showed most potent antiproliferative activity towards A-549 cells. Whereas, Compounds 184, 227, 247, and 269 showed promising inhibitory activity towards MCF-7 cells. It has also been noticed that compounds 149, 237, 253 and 267 displayed the strongest antiproliferative activity against MDA-MB-231 cells. All these molecules, when screened against non-cancer fibroblast NIH/3T3 cells showed no cytotoxic effect. This suggests the selectivity of cells toward cancer cells over non-cancer cells. Furthermore, the inhibitory activity of synthesized derivatives against MCT1 was determined by using a 3-bromopyruvate (3-BP) functional assay in A-549 cells to assess the MCT1..